Inhibitory cell adhesion surfaces

• US 20080275546A1
• Filed: 04/24/2008
• Published: 11/06/2008
• Est. Priority Date: 05/03/2007
• Status: Abandoned Application

• Current Assignee: Nanosurface Technologies Llc
• Original Assignee: Chameleon Scientific Corporation (Nanosurface Technologies Llc)
• Inventors: Kitchell, Barbara S., Ryves, Luke J., Storey, Daniel M.
• Application Number:
  US12/148,971
• Publication Number:
  US 20080275546A1
• Time in Patent Office: Days
• US Class Current: 623/1.46
• CPC Class Codes: A61F 2/0077 Special surfaces of prostheses, e.g. for improving ingrowth A61F2/30767 takes precedence
• CPC Class Codes: A61F 2/30767 Special external or bone-contacting surface, e.g. coating for improving bone ingrowth
• CPC Class Codes: A61F 2/3094 Designing or manufacturing processes
• CPC Class Codes: A61F 2002/009 for hindering or preventing attachment of biological tissue
• CPC Class Codes: A61F 2002/30092 using shape memory or superelastic materials, e.g. nitinol
• CPC Class Codes: A61F 2002/30932 for retarding or preventing ingrowth of bone tissue
• CPC Class Codes: A61F 2210/0014 using shape memory or superelastic materials, e.g. nitinol
• CPC Class Codes: A61F 2240/001 Designing or manufacturing processes
• CPC Class Codes: A61F 2310/00023 Titanium or titanium-based alloys, e.g. Ti-Ni alloys
• CPC Class Codes: A61F 2310/00029 Cobalt-based alloys, e.g. Co-Cr alloys or Vitallium
• CPC Class Codes: C23C 14/20 on organic substrates
• CPC Class Codes: C23C 14/325 Electric arc evaporation

Abstract

Textured nanostructured surfaces are described which are highly resistant to cell adhesion. Such surfaces on medical implants inhibit fibroblast adhesion particularly on titanium treated silicone. The surfaces can also be engineered so that other cell types, such as endothelial and osteoblast cells, show little if any tendency to attach to the surface in vivo.

Claims

1. A method for treating a selected target surface to provide increased surface hydrophobicity, comprising the steps:

exposing the target surface to an ionic plasma comprising activated metal ions;

selecting conditions to allow deposition of controlled size nanoparticles on the target surface;

wherein the deposited nanoparticles impart increased surface hydrophobicity compared to the target surface before exposure to the ionic plasma.

2. The method of claim 1 wherein the treated target surface has a higher surface energy than the untreated target surface.

3. The method of claim 1 wherein the selected target surface is a metal or polymer.

4. The method of claim 3 wherein the metal is titanium, Ti6Al4V or CoCrMo.

5. The method of claim 3 wherein the polymer is polyethylene, silicone, ultra high molecular weight polyethylene (UHMWPE), or polytetrafluoroethylene (PTFE).

7. The implant device of claim 5 wherein the cell resistant to adhesion is a fibroblast, endothelial or osteoblast cell.

6. A titanium implant device having a nanostructured high energy surface resistant to cell adhesion in vivo wherein the surface comprises sufficient number of ionic plasma deposited nanoparticles to increase hydrophobicity.

8. A method for altering the surface energy of a substrate surface, comprising:

depositing titanium nanoparticulates onto a selected surface by ionic plasma deposition (IPD); and

monitoring the hydrophobicity of the surface-deposited nanoparticulates;

wherein a change in surface hydrophobicity is indicative of an increase or decrease in surface energy compared with surface energy of the selected surface before deposition of titanium nanoparticles.

9. The method of claim 8 wherein the selected surface is polyethylene, silicone, UHMWPE, or PTFE.

10. The method of claim 8 wherein the selected surface is titanium or a titanium alloy.

11. The method of claim 8 wherein the ionic plasma target comprises titanium.

12. The method of claim 8 wherein the ionic plasma target comprises nitinol.

13. A medical device having a surface comprising an ionic plasma deposited (IPD) titanium hydrophobic coating inhibitory to cell adhesion.

14. The medical device of claim 13 wherein the surface of the medical device is silicone, ultra high molecular weight polyethylene (UHMWPE) or polytetrafluoroethylene (PTFE).

15. The medical device of claim 13 wherein a cell selected from the group consisting of fibroblasts, endothelial cells and osteoblasts are inhibited from adhering to the surface.

16. The medical device of claim 13 which is a stent, indwelling catheter, heart valve, polymer breast implants, joint implants, implanted leads for neural stimulation or pacemakers.